Jan 30, 2019
MediSieve Receives Two Grants, Totalling £1.56M From Innovate UK
MediSieve is delighted to announce that it is receiving two grants from Innovate UK, worth a total of around £1.56m.
LONDON – January 30, 2019 – MediSieve is delighted to announce that it is receiving two grants from Innovate UK, worth a total of around £1.56m. One large biomedical catalyst grant will progress development of a severe sepsis product, developing five magnetic particles to remove different sepsis targets. Another SRBI grant enables further focus on one of those particles and how it can be used to remove anti-microbial resistant (AMR) bacteria from a patient’s bloodstream. Both are 2-year projects starting in 2019.
The Biomedical Catalyst (BMC) project aims to develop a multi-target magnetic blood filtration treatment that is complimentary to antibiotics, working to address the LPS and cytokines that antibiotics release and which exacerbate the immune response and elevate cytokine levels. The SBRI project explores an alternative to antibiotics to reduce the level of bacteria in the bloodstream of AMR sepsis patients, with the added benefit of LPS removal as a secondary effect.
Both projects involve distinct experimental pathways which can be delivered simultaneously with the added benefit that areas of synergy and overlap reduce workload. Whilst the SBRI project focuses exclusively on targeting and removing E. coli, the BMC project does not include any E. coli or other bacterial testing. The SBRI project includes a clinical trial, whereas the BMC does not.
Speaking about the biomedical catalyst grant Dr George Frodsham, CEO and founder of MediSieve, says, "Our technology is like dialysis, circulating a patient's blood through an external loop to remove disease-causing targets. While dialysis relies on non-specific size-based filtration, MediSieve uses magnetic particles coated with antibodies (Ab-MP) to target specific components, and a magnetic filter to extract them.
"The patented MediSieve Filter (MF) can safely remove magnetic components from the bloodstream. It is already developed as a treatment for severe malaria (Ab-MPs are not required for malaria, since malaria infected cells exhibit naturally occurring magnetic properties). The MF has completed pre-clinical testing and will enter first-in-man clinical trials in 2019.
"This project concerns the development of the Ab-MP to apply our technology to Sepsis. Sepsis is caused by an infection that creates a dysregulated immune response which can escalate to septic shock. The destruction of bacteria by the immune system or antibiotics creates large quantities of endotoxins, which aggravate the immune response, causing the over-production of inflammatory cytokines and a cascade towards septic shock. Antibiotics kill pathogens, but do not remove them from the bloodstream, so the immune system's overreaction continues.
"Our Ab-MPs target LPS, gram-negative bacteria, specific cytokines and damage associated molecular patterns (DAMP), rapidly reducing the levels in a patient's bloodstream. Used in combination with antibiotics, it could help eliminate the infection, and reverse the escalation to septic shock. Treatment of sepsis with antibiotics increases the LPS load in the bloodstream, since LPS persist after the pathogens have been killed. LPS, inflammatory cytokine and DAMP levels correlate with clinical outcomes, and their removal would be beneficial in helping to treat the disease.
"This project will focus on the development of the Ab-MP to target LPS, cytokines and DAMP, proving their safety and efficacy in both laboratory and pre-clinical safety and efficacy trials, and performing the biocompatibility testing required in order to progress the treatment to first-in-man clinical trials."
Being awarded both grants is especially motivating because it enables areas of overlap and synergy across the research in:
• regulatory work
• expertise and know-how
• the opportunity to include some or all of the Ab-MPs from the BMC project in the clinical trial of the SBRI project.
This improves the chances of rapid and successful outcomes of both projects.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: